Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lipoprotein(a) levels can guide CV risk assessment and treatment

Publish date:: June 5, 2019

Key clinical point: High levels of lipoprotein(a) are an independent risk factor for atherosclerotic cardiovascular disease.

Major finding: Serum Lp(a) levels can be used to decide patient risk and treatment options for cardiovascular disease.

Study details: Scientific statement from the National Lipid Association.

Disclosures: Five authors disclosed honorarium or advisory board positions with the pharmaceutical sector. No other conflicts of interest were declared.

Citation:

Wilson D et al. J Clin Lipidol. 2019 May 17. doi: 10.1016/j.jacl.2019.04.010.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,